Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesPension (IS)Profit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateWages, Salaries and Other
Others
Ratios

Harvard Bioscience (HBIO) Other Non Operating Income (2016 - 2025)

Harvard Bioscience (HBIO) has disclosed Other Non Operating Income for 16 consecutive years, with -$365000.0 as the latest value for Q3 2025.

  • On a quarterly basis, Other Non Operating Income rose 29.54% to -$365000.0 in Q3 2025 year-over-year; TTM through Sep 2025 was -$1.1 million, a 2.47% increase, with the full-year FY2024 number at -$652000.0, down 187.22% from a year prior.
  • Other Non Operating Income was -$365000.0 for Q3 2025 at Harvard Bioscience, up from -$644000.0 in the prior quarter.
  • In the past five years, Other Non Operating Income ranged from a high of $465000.0 in Q4 2022 to a low of -$644000.0 in Q2 2025.
  • A 5-year average of -$135578.9 and a median of -$179000.0 in 2022 define the central range for Other Non Operating Income.
  • Peak YoY movement for Other Non Operating Income: surged 453.85% in 2023, then crashed 1251.11% in 2024.
  • Harvard Bioscience's Other Non Operating Income stood at -$189000.0 in 2021, then skyrocketed by 346.03% to $465000.0 in 2022, then tumbled by 171.4% to -$332000.0 in 2023, then soared by 156.93% to $189000.0 in 2024, then crashed by 293.12% to -$365000.0 in 2025.
  • Per Business Quant, the three most recent readings for HBIO's Other Non Operating Income are -$365000.0 (Q3 2025), -$644000.0 (Q2 2025), and -$324000.0 (Q1 2025).